

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 7, 2005

ENZO BIOCHEM, INC.

(Exact Name of Registrant as Specified in Its Charter)

NEW YORK

(State or Other Jurisdiction of Incorporation)

1-09974

13-2866202

(Commission File Number)

(IRS Employer Identification No.)

60 EXECUTIVE BOULEVARD
FARMINGDALE, NEW YORK 11735

(Address of Principal Executive Offices)

(631) 755-5500

(Registrant's Telephone Number, Including Area Code)

NOT APPLICABLE

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

On June 7, 2005, Enzo Biochem, Inc. (the "Company") issued a press release announcing it will hold a conference call to discuss its fiscal 2005 third quarter results on Thursday, June 9, 2005, at 4:45 PM ET. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c)

Exhibit No.	Description
-------------	-------------

99.1	Press Release of Enzo Biochem, Inc. dated June 7, 2005.
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

By: /s/ Barry Weiner

Barry Weiner
President and Chief Financial Officer

Dated: June 7, 2005

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of Enzo Biochem, Inc. dated June 7, 2005.

[OBJECT OMITTED]

[OBJECT OMITTED]
Enzo Biochem, Inc.
527 Madison Avenue
New York, NY 10022

ENZO BIOCHEM, INC. SCHEDULES FISCAL 2005 THIRD QUARTER OPERATING
RESULTS TELECONFERENCE FOR THURSDAY JUNE 9, 2005, AT 4:45 PM E.T.

FARMINGDALE, NY, June 7, 2005 - Enzo Biochem, Inc. (NYSE:ENZ), will hold a conference call to discuss its fiscal 2005 third quarter results on Thursday, June 9, 2005, at 4:45 PM ET, it was announced today by Barry Weiner, President.

To listen to the conference call dial 1-800-322-0079. International callers can dial 1-973-935-2100. Dial in approximately ten minutes prior to the scheduled teleconference time. A rebroadcast of the call will be available starting two hours after the conference call ends, through midnight (ET) on Friday, June 24, 2005. The replay of the conference call can be accessed by dialing 1-877-519-4471, and, when prompted, use PIN number 6109512. International callers can dial 1-973-341-3080, using the same PIN number.

Enzo's conference call can also be accessed live over the Internet at <http://www.vcall.com>. To listen to the live call, individuals should go to the web site at least 15 minutes early to register, download and install any necessary audio software. A replay on the Vcall website will be available for one week after the original broadcast.

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

###

Contact:

For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232

Or

Ed Lewis, CEOcast, Inc., 212-732-4300